Supernus Pharmaceuticals Inc logo

Supernus Pharmaceuticals Inc

$ 33.75 -0.51 (-1.49%) 04:00 PM EST
On watch
P/E:
33.43
P/B:
2.15
Market Cap:
$ 1.81B
Enterprise V:
$ 1.92B
Volume:
465.08K
Avg Vol (2M):
433.31K
Also Trade In:
Volume:
465.08K
Market Cap $:
1.81B
PE Ratio:
33.43
Avg Vol (2-Month):
433.31K
Enterprise Value $:
1.92B
PB Ratio:
2.15
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The company products include Oxtellar XR, Trokendi XR, SPN-812, and others. The majority of the revenue is generated from the sale of Trokendi XR.
Name Current Vs Industry Vs History
Cash-To-Debt 0.81
Equity-to-Asset 0.5
Debt-to-Equity 0.53
Debt-to-EBITDA 3.3
Interest Coverage 3.5
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.07
Distress
Grey
Safe
Beneish M-Score -2.6
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 63.11
9-Day RSI 55.78
14-Day RSI 53.98
6-1 Month Momentum % 7.84
12-1 Month Momentum % 28.99

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.85
Quick Ratio 0.73
Cash Ratio 0.49
Days Inventory 375.75
Days Sales Outstanding 83.78
Days Payable 73.06

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -0.6

Financials (Next Earnings Date:2022-11-03 Est.)

SUPN's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:SUPN

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 630.071
EPS (TTM) ($) 1.01
Beta 0.82
Volatility % 23.3
14-Day RSI 53.98
14-Day ATR ($) 1.136609
20-Day SMA ($) 34.0215
12-1 Month Momentum % 28.99
52-Week Range ($) 24.95 - 36.08
Shares Outstanding (Mil) 53.5

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Supernus Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Supernus Pharmaceuticals Inc Analysis

Share your research

Headlines

See More
No news.